8-K: Zymeworks' Ziihera Shines in HER2+ GEA Phase 3 Trial

Zymeworks announced positive topline results from its Phase 3 HERIZON-GEA-01 trial, indicating Ziihera's potential as a new standard of care for first-line HER2-positive gastroesophageal adenocarcinoma.

Summary

• Ziihera (zanidatamab-hrii) plus chemotherapy demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy.
• Ziihera plus chemotherapy showed a clinically meaningful effect with a strong trend toward statistical significance for overall survival (OS) at the first OS interim analysis.
• Ziihera plus Tevimbra (tislelizumab) and chemotherapy achieved clinically meaningful and statistically significant improvements in both OS and PFS versus trastuzumab and chemotherapy.
• A PFS and OS benefit was observed in the Ziihera plus Tevimbra and chemotherapy arm in both PD-L1 positive and PD-L1 negative subgroups.
• Improvements were also demonstrated in key secondary endpoints, including objective response rate (ORR) and duration of response (DoR), supporting the primary efficacy endpoints.
• The safety profile of Ziihera in combination with chemotherapy, with or without Tevimbra, was generally consistent with the known safety profile of each agent, with no new safety signals observed.

Sentiment

Score: 9

Explanation: The filing reports highly positive topline results from a Phase 3 trial, showing statistically significant and clinically meaningful improvements in primary and secondary endpoints for a difficult-to-treat cancer. This indicates a strong potential for a new standard of care and future regulatory approval, significantly de-risking the asset.

Positives

• Statistically significant and clinically meaningful improvement in PFS for Ziihera plus chemotherapy compared to the control arm.
• Clinically meaningful effect with a strong trend toward statistical significance for OS for Ziihera plus chemotherapy at the first interim analysis.
• Statistically significant and clinically meaningful improvements in both OS and PFS for Ziihera plus Tevimbra and chemotherapy.
• PFS and OS benefits observed in both PD-L1 positive and PD-L1 negative subgroups for the Ziihera plus Tevimbra and chemotherapy arm.
• Improvements in key secondary endpoints (ORR and DoR) supporting the primary efficacy endpoints.
• Safety profile consistent with known agents, with no new safety signals observed, supporting a favorable overall benefit-risk.
• Results highlight Ziihera's potential to be the HER2-targeted agent-of-choice and a new standard of care in first-line HER2-positive gastroesophageal adenocarcinoma.
• Reinforces the strength of Zymeworks' Azymetric platform to engineer novel and differentiated multifunctional biologics.

Risks

• Any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable.
• Zymeworks may not achieve milestones or receive additional payments under its collaborations.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials.
• The impact of new or changing laws and regulations.
• Market conditions, including the impact of tariffs.
• Potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments.
• Changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls.
• The impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors.
• Zanidatamab may not be successfully commercialized.
• Ongoing or future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates.
• Data providing early validation of the ADC platform and next-generation pipeline programs may not be replicated in future studies.
• Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect.
• Inability to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Jazz Pharmaceuticals expects to submit a supplemental Biologics License Application (sBLA) in the first half of 2026 to support Ziihera as a first-line treatment for HER2+ locally advanced or metastatic GEA. Zymeworks anticipates an additional planned OS interim analysis for Ziihera plus chemotherapy in mid-2026. The company also plans to present the data at a major medical meeting in the first quarter of 2026, publish in a peer-reviewed journal, and rapidly submit for adoption in the National Comprehensive Cancer Network Guidelines (NCCN Guidelines).

Management Comments

• "The topline results from HERIZON-GEA-01 represent a true turning point for patients with HER2+ gastroesophageal adenocarcinoma, marking real progress in an indication that has historically had limited treatment options and poor outcomes."
• "These data highlight the potential of zanidatamab to transform the standard of care in HER2+ indications, demonstrate the strength of our Azymetric platform to engineer novel and differentiated multifunctional biologics, and reinforce the strategic value of our partnership strategy with Jazz and BeOne in bringing this critical therapy to patients worldwide."

Industry Context

The positive results for Ziihera in first-line HER2+ GEA are highly significant for an indication that has historically suffered from limited treatment options and poor patient outcomes. Ziihera's demonstrated superiority over trastuzumab and chemotherapy, which represents a current standard of care, positions it as a potential new 'agent-of-choice' and 'new standard of care.' This could lead to a substantial shift in the treatment paradigm for HER2+ gastroesophageal adenocarcinoma, allowing Zymeworks and its partners to capture a significant market share.

Comparison to Industry Standards

• Ziihera plus chemotherapy demonstrated superior progression-free survival (PFS) compared to trastuzumab and chemotherapy, which served as the control arm and represents a current standard of care.
• Ziihera plus Tevimbra and chemotherapy demonstrated superior overall survival (OS) and PFS compared to trastuzumab and chemotherapy.
• Zanidatamab is already approved in the U.S., Europe, and China for second-line biliary tract cancer (BTC) and is the first and only dual HER2-targeted bispecific antibody approved for that indication, setting a high benchmark for its class.

Stakeholder Impact

• Shareholders: Highly positive impact due to significant clinical success, potential for new standard of care, future regulatory approvals, and associated milestone payments and royalties.
• Patients with HER2+ GEA: Significant positive impact by offering a new, more effective first-line treatment option for a disease with historically poor outcomes.
• Healthcare Providers: New treatment option to consider, potentially improving patient outcomes.
• Partners (Jazz and BeOne): Positive impact through successful development and commercialization of a key asset.
• Employees: Positive impact on morale and company outlook due to successful clinical development.

Next Steps

• Jazz Pharmaceuticals intends to submit a supplemental Biologics License Application (sBLA) in the first half of 2026.
• Jazz plans to submit the data for presentation at a major medical meeting in the first quarter of 2026.
• Jazz plans to submit the data for publication in a peer-reviewed journal.
• Jazz will rapidly submit for adoption in the National Comprehensive Cancer Network Guidelines (NCCN Guidelines).
• An additional planned OS interim analysis for Ziihera plus chemotherapy is expected in mid-2026.
• Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, with Phase 1 studies for ZW191 and ZW251 actively recruiting.

Key Dates

Recommendation

The positive topline Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma are highly significant, demonstrating statistically meaningful and clinically impactful improvements in both progression-free survival and overall survival. This positions Ziihera as a potential new standard of care in a difficult-to-treat indication with limited options, suggesting substantial market potential. The planned sBLA submission in 1H 2026 and eligibility for future milestones and royalties further de-risk the investment and indicate strong future revenue streams. The consistent safety profile also supports a favorable benefit-risk assessment. This news represents a major positive catalyst for Zymeworks.

Keywords

Zymeworks, ZYME, Ziihera, zanidatamab, HER2-positive, gastroesophageal adenocarcinoma, GEA, stomach cancer, esophageal cancer, gastroesophageal junction cancer, Phase 3, HERIZON-GEA-01, clinical trial, oncology, biotechnology, bispecific antibody, Azymetric platform, Jazz Pharmaceuticals, BeOne Medicines, progression-free survival, overall survival, FDA, sBLA, Breakthrough Therapy, Fast Track, Orphan Drug